Pompilio, G., Morabito, A., Cortinovis, D.L. and Integlia, D. 2022. Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. Global and Regional Health Technology Assessment. 9, 1 (Jan. 2022), 22–29. DOI:https://doi.org/10.33393/grhta.2022.2351.